These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 30959357)

  • 61. Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.
    Betsch A; Rutgeerts O; Fevery S; Sprangers B; Verhoef G; Dierickx D; Beckers M
    Blood Rev; 2018 Nov; 32(6):490-498. PubMed ID: 29691090
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression.
    Ohl K; Tenbrock K
    Front Immunol; 2018; 9():2499. PubMed ID: 30425715
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Roles of Myeloid-Derived Suppressor Cell Subpopulations in Autoimmune Arthritis.
    Li M; Zhu D; Wang T; Xia X; Tian J; Wang S
    Front Immunol; 2018; 9():2849. PubMed ID: 30564242
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.
    Zöller M
    Front Immunol; 2018; 9():137. PubMed ID: 29456536
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Activation of immunosuppressive network in the aging process.
    Salminen A
    Ageing Res Rev; 2020 Jan; 57():100998. PubMed ID: 31838128
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell Interaction.
    Yang T; Li J; Li R; Yang C; Zhang W; Qiu Y; Yang C; Rong R
    Curr Gene Ther; 2019; 19(2):81-92. PubMed ID: 31237207
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon?
    Su Z; Ni P; Zhou C; Wang J
    Scand J Immunol; 2016 Nov; 84(5):255-261. PubMed ID: 27541573
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Myeloid derived-suppressor cells: their role in cancer and obesity.
    Ostrand-Rosenberg S
    Curr Opin Immunol; 2018 Apr; 51():68-75. PubMed ID: 29544121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.
    Bhardwaj V; Ansell SM
    Front Cell Dev Biol; 2023; 11():1129343. PubMed ID: 37091970
    [TBL] [Abstract][Full Text] [Related]  

  • 74. "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.
    Wang T; Hu Y; Dusi S; Qi F; Sartoris S; Ugel S; De Sanctis F
    Front Immunol; 2023; 14():1130060. PubMed ID: 36911674
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aging Affects the Role of Myeloid-Derived Suppressor Cells in Alloimmunity.
    Schroeter A; Roesel MJ; Matsunaga T; Xiao Y; Zhou H; Tullius SG
    Front Immunol; 2022; 13():917972. PubMed ID: 35874716
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of the P2X7 receptor in myeloid-derived suppressor cells and immunosuppression.
    Principi E; Raffaghello L
    Curr Opin Pharmacol; 2019 Aug; 47():82-89. PubMed ID: 30959357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
    Consonni FM; Porta C; Marino A; Pandolfo C; Mola S; Bleve A; Sica A
    Front Immunol; 2019; 10():949. PubMed ID: 31130949
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative.
    Karin N
    Front Immunol; 2020; 11():557586. PubMed ID: 33193327
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 4.